Cholesterol absorption and synthesis markers in individuals with and without a CHD event during pravastatin therapy: Insights from the PROSPER trial

Journal of Lipid Research

Volumn 51, Issue 1, 2010, Pages 202-209

  Matthan, Nirupa R ^a,b   Resteghini, Nancy ^a   Robertson, Michele ^c   Ford, Ian ^c   Shepherd, James ^c   Packard, Chris ^c   Buckley, Brendan M ^d   Jukema, J Wouter ^e   Lichtenstein, Alice H ^b   Schaefer, Ernst J ^a  

^a TUFTS UNIVERSITY   (United States)

^b TUFTS UNIVERSITY   (United States)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d UNIVERSITY COLLEGE CORK   (Ireland)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Desmosterol; Lathosterol; Lipoproteins; Phytosterols

Indexed keywords

CAMPESTEROL; DESMOSTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LATHOSTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; SITOSTEROL; TRIACYLGLYCEROL;

ABSORPTION; AGED; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CHOLESTEROL SYNTHESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HOMEOSTASIS; HUMAN; ISCHEMIC HEART DISEASE; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; AGED, 80 AND OVER; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY DISEASE; DESMOSTEROL; FEMALE; HOMEOSTASIS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; PHYTOSTEROLS; PRAVASTATIN; SITOSTEROLS; TRIGLYCERIDES;

EID: 73149119778     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M900032-JLR200     Document Type: Article

References (26)

1. AHA. 2007. Heart disease and stroke statistics-2007 update. Accessed January 2009, at http://www.americanheart.org/ presenter.jhtml?identifier=1928.
2. National Cholesterol Education Program (NCEP) Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). 2002. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 106: 3143-3421.
3. Baigent, C., A. Keech, P. M. Kearney, L. Blackwell, G. Buck, C. Pollicino, A. Kirby, T. Sourjina, R. Peto, R. Collins, et al. for the Cholesterol Treatment Trialists' (CTT) Collaborators. 2005. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 366: 1267-1278.
4. Heart Protection Study Collaborative Group. 2002. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 360: 23-33.
5. Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. 1998. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med. 339: 1349-1357.
6. Nakamura, H., and MEGA Study Group. 2007. Primary prevention of cardiovascular diseases among hypercholesterolemic Japanese with a low dose of pravastatin. Atheroscler. Suppl. 8: 13-17.
7. Sacks, F. M., M. A. Pfeffer, L. A. Moye, J. L. Rouleau, J. D. Rutherford, T. G. Cole, L. Brown, J. W. Warnica, J. M. Arnold, C. C. Wun, et al. 1996. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N. Engl. J. Med. 335: 1001-1009.
8. The Scandinavian Simvastatin Survival Study. 1994. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 344: 1386-1389.
9. Ward, S., M. Lloyd Jones, A. Pandor, M. Holmes, R. Ara, A. Ryan, W. Yeo, and N. Payne. 2007. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol. Assess. 11: 1-160.
10. West of Scotland Coronary Prevention Study Group. 1995. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N. Engl. J. Med. 333: 1301-1307.
11. Shepherd, J., G. J. Blauw, M. B. Murphy, E. L. Bollen, B. M. Buckley, S. M. Cobbe, I. Ford, A. Gaw, M. Hyland, J. W. Jukema, et al., on behalf of the PROSPER study group. 2002. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 360: 1623-1630.
12. Knopp, R. H., P. Paramsothy, B. Atkinson, and A. Dowdy. 2008. Comprehensive lipid management versus aggressive low-density lipoprotein lowering to reduce cardiovascular risk. Am. J. Cardiol. 101: 48B-75B.
13. Miettinen, T. A., and H. Gylling. 2002. Ineffective decrease of serum cholesterol by simvastatin in a subgroup of hypercholesterolemic coronary patients. Atherosclerosis. 164: 147-152.
14. van Himbergen, T. M., N. R. Matthan, N. A. Resteghini, S. Otokozawa, M. Ai, E. A. Stein, P. H. Jones, and E. J. Schaefer. 2009. Comparison of the effects of maximal dose atorvastatin and rosuvastatin therapy on cholesterol synthesis and absorption markers. J. Lipid Res. 50: 730-739.
15. Friedewald, W. T., R. I. Levy, and D. S. Fredrickson. 1972. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 18: 499-502.
16. Matthan, N. R., A. Giovanni, E. J. Schaefer, B. G. Brown, and A. H. Lichtenstein. 2003. Impact of simvastatin, niacin, and/or antioxidants on cholesterol metabolism in CAD patients with low HDL. J. Lipid Res. 44: 800-806.
17. Matthan, N. R., J. M. LaRocque, M. Pencina, R. B. D'Agostino, E. J. Schaefer, and A. H. Lichtenstein. 2009. Alterations in cholesterol absorption and synthesis characterize Framingham Offspring Study participants with coronary heart disease. J. Lipid Res. 50: 1927- 1935.
18. Reihner, E., M. Rudling, D. Stahlberg, L. Berglund, S. Ewerth, I. Bjorkhem, K. Einarsson, and B. Angelin. 1990. Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol. N. Engl. J. Med. 323: 224-228.
19. Miettinen, T. A., H. Gylling, T. Strandberg, and S. Sarna. 1998. Baseline serum cholestanol as predictor of recurrent coronary events in subgroup of Scandinavian simvastatin survival study. Finnish 4S investigators. BMJ. 316: 1127-1130.
20. Miettinen, T. A., T. E. Strandberg, and H. Gylling. 2000. Noncholesterol sterols and cholesterol lowering by long-term simvastatin treatment in coronary patients: relation to basal serum cholestanol. Arterioscler. Thromb. Vasc. Biol. 20: 1340-1346.
21. Gylling, H., and T. A. Miettinen. 2002. Baseline intestinal absorption and synthesis of cholesterol regulate its response to hypolipidaemic treatments in coronary patients. Atherosclerosis 160: 477-481.
22. Navab, M., R. Yu, N. Gharavi, W. Huang, N. Ezra, A. Lotfizadeh, G. M. Anantharamaiah, N. Alipour, B. J. Van Lenten, S. T. Reddy, et al. 2007. High-density lipoprotein: antioxidant and anti-inflammatory properties. Curr. Atheroscler. Rep. 9: 244-248.
23. Ansell, B. J., M. Navab, S. Hama, N. Kamranpour, G. C. Fonarow, G. Hough, S. Rahmani, R. Mottahedeh, R. Dave, S. T. Reddy, et al. 2003. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from cholesterol subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation. 108: 2751-2756.
24. Niemi, M., P. J. Neuvonen, U. Hofman, J. T. Backman, M. Schwab, D. Lutjohann, K. Von Bergmann, M. Eichelbaum, and K. T. Kivisto. 2005. Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype*17. Pharmacogenet. Genomics. 15: 303-309.
25. Plösch, T., A. Kosters, A. K. Groen, and F. T. Kuipers. 2005. The ABC of hepatic and intestinal cholesterol transport. Handb. Exp. Pharmacol. 170: 465-482.
26. Polisecki, E., H. Muallem, N. Maeda, I. Peter, M. Robertson, A. D. McMahon, I. Ford, C. Packard, J. Shepherd, J. W. Jukema, et al. on behalf of the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) Investigators. 2008. Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER. Atherosclerosis. 200: 109-114.